Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026, highlighting the company's commitment to advancing its pipeline of central nervous system (CNS) and immunology treatments. The conferences provide a platform for Tonix to showcase its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years, as well as its broader portfolio.
Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach. These events offer opportunities for Tonix to engage with investors and analysts, providing updates on its commercial and clinical progress.
Tonix is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments in areas of high unmet medical need. Beyond TONMYA, the company's CNS commercial infrastructure supports its marketed acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, the CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
In the immunology space, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs underscore the company's diversified approach to addressing significant medical needs.
The company's participation in these conferences comes at a pivotal time, as it seeks to maximize the commercial potential of TONMYA and advance its late-stage pipeline. Investors will be keen to hear updates on clinical trial progress, commercial strategy, and potential partnerships. The full press release is available here.
Tonix Pharmaceuticals Holding Corp. continues to build momentum with its CNS and immunology portfolio. The company's newsroom provides additional updates on TNXP developments here.
